Evaluation of DTRAX Graft in Patients With Cervical Degenerative Disc Disease
This study is enrolling participants by invitation only.
Information provided by (Responsible Party):
Providence Medical Technology, Inc.
First received: June 7, 2012
Last updated: January 13, 2013
Last verified: January 2013
DTRAX Graft is used to relieve nerve pressure in the neck in order to provide relief for Cervical Degenerative Disc Disease. This study is being conducted to determine the effectiveness of the graft, and to find out whether or not it provides better results or faster healing than traditional ways of performing surgery for Cervical Degenerative Disc Disease.
Cervical Degenerative Disc Disease
Device: DTRAX Graft
||Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
||Evaluation of DTRAX Graft in Patients With Cervical Degenerative Disc Disease
Primary Outcome Measures:
Secondary Outcome Measures:
- Safety information will be evaluated by collecting the type, frequency, severity, device, and procedure-relatedness of adverse events. [ Time Frame: Baseline throughout 12 months post-operatively ] [ Designated as safety issue: No ]
| Estimated Enrollment:
| Study Start Date:
| Estimated Study Completion Date:
| Estimated Primary Completion Date:
||February 2014 (Final data collection date for primary outcome measure)
Device: DTRAX Graft
DTRAX Graft is an allograft implant inserted to support spinal fusion.
|Ages Eligible for Study:
||35 Years to 80 Years
|Genders Eligible for Study:
|Accepts Healthy Volunteers:
Subject diagnosed with DDD in C3-C7, defined as follows:
Subject has single-level disease, OR multi-level disease demonstrated radiographically, and confirmed to be symptomatic by one of the following methods:
- Selective nerve root block, OR
- EMG, OR
- Distinctive clinical examination.
- Subject has dynamic stenosis relieved by traction and made worse by a Spurlings maneuver.
- Subject is 35-80 years of age, inclusive.
- Subject is unresponsive to 6 weeks conservative, nonoperative treatment, or has the presence of progressive symptoms or signs of nerve root compression in face of combined nonoperative management.
- Preoperative NDI score of ≥ 30.
- Preoperative neck pain and arm pain score of ≥ 6 on Neck and Arm Pain Scales.
- Patient is a male or non-pregnant, non-lactating female.
- Female patients of child-bearing potential, including those who have had a tubal ligation, but excluding those who have not experienced a menstrual period for at least two years, must have a negative urine pregnancy test at Screening.
- Patient must voluntarily provide written, informed consent.
- Subject is able to meet the proposed follow-up schedule.
- Subject is able to follow the postoperative management program.
- Subject has severe osteopenia, osteoporosis, osteomalacia, spinal metastases, or metabolic bone disease OR the level of BMD is a T score of -2.5 or below OR patient has sustained a vertebral compression or nontraumatic hip or wrist fracture.
- Subject has overt or active spinal and/or systemic infection.
- Subject has spondylolisthesis ≥ 3.5mm or rotator subluxation.
- Subject has cervical myelopathy.
- Subject has a chronic pain syndrome.
- Subject has radicular findings with major motor impairment.
- Subject has a condition that requires postoperative medications that interfere with fusion or the stability of the implant, such as steroids.
- Subject is mentally incompetent.
- Subject is a prisoner.
- Subject is pregnant.
- Subject abuses alcohol or drugs.
- Subject has a cervical spinal condition other than symptomatic cervical disc disease requiring surgical treatment at the involved level.
- Subject has insulin dependent diabetes.
- Subject has chronic or acute renal failure or prior history of renal disease.
- Subject has fever at the time of surgery, defined as > 38.5 degrees C.
- Subject has documented allergy or intolerance to stainless steel, titanium, or a titanium alloy.
- Subject has received drugs which may interfere with bone metabolism within two weeks prior to the planned date of DTRAX surgery.
- Subject has history of an endocrine or metabolic disorder known to affect osteogenesis .
- Subject has had treatment with an investigational therapy within 28 days prior to DTRAX surgery or such treatment is planned during the 16 weeks following implantation of DTRAX Graft.
- Subject is involved in spinal litigation or Workmen's Compensation claim.
- Subject is obese, defined as body mass index (BMI) > 35.
- Patient has psychiatric history, head injury or any other condition, which, in the Investigator's opinion, would prevent the patient from complying with postoperative follow-up visits.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01616719
|Neurospine Institute Medical Group
|San Francisco, California, United States, 94115 |
|Office of Dr. Brian Andrews, Neurosurgery
|San Francisco, California, United States, 94114 |
Providence Medical Technology, Inc.
||Bruce McCormack, M.D.
||Neurospine Institute Medical Group
||Brian Andrews, M.D.
||Office of Dr. Brian Andrews, Neurosurgery
No publications provided
||Providence Medical Technology, Inc.
History of Changes
|Other Study ID Numbers:
|Study First Received:
||June 7, 2012
||January 13, 2013
||United States: Institutional Review Board
Additional relevant MeSH terms:
ClinicalTrials.gov processed this record on June 13, 2013
Intervertebral Disk Degeneration
Peripheral Nervous System Diseases
Nervous System Diseases